File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of recurrent hepatocellular carcinoma after liver transplant

TitleManagement of recurrent hepatocellular carcinoma after liver transplant
Authors
KeywordsTransarterial radioembolization
Hepatocellular carcinoma
Immunosuppression
Liver transplantation
Radiofrequency ablation
Recurrence
Resection
Stereotactic body radiation therapy
Targeted therapy
Transarterial chemoembolization
Issue Date2015
Citation
World Journal of Hepatology, 2015, v. 7, n. 8, p. 1142-1148 How to Cite?
Abstract© The Author(s) 2015. Hepatocellular carcinoma (HCC) is the leading cause of deaths in patients with hepatitis B or C, and its incidence has increased considerably over the past decade and is still on the rise. Liver transplantation (LT) provides the best chance of cure for patients with HCC and liver cirrhosis. With the implementation of the MELD exception system for patients with HCC waitlisted for LT, the number of recipients of LT is increasing, so is the number of patients who have recurrence of HCC after LT. Treatments for intrahepatic recurrence after transplantation and after other kinds of surgery are more or less the same, but long-term cure of posttransplant recurrence is rarely seen as it is a "systemic" disease. Nonetheless, surgical resection has been shown to be effective in prolonging patient survival despite the technical difficulty in resecting graft livers. Besides surgical resection, different kinds of treatment are also in use, including transarterial chemoembolization, radiofrequency ablation, high-intensity focused ultrasound ablation, and stereotactic body radiation therapy. Targeted therapy and modulation of immunosuppressants are also adopted to treat the deadly disease.
Persistent Identifierhttp://hdl.handle.net/10722/221379
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorChok, KSH-
dc.date.accessioned2015-11-18T06:09:09Z-
dc.date.available2015-11-18T06:09:09Z-
dc.date.issued2015-
dc.identifier.citationWorld Journal of Hepatology, 2015, v. 7, n. 8, p. 1142-1148-
dc.identifier.urihttp://hdl.handle.net/10722/221379-
dc.description.abstract© The Author(s) 2015. Hepatocellular carcinoma (HCC) is the leading cause of deaths in patients with hepatitis B or C, and its incidence has increased considerably over the past decade and is still on the rise. Liver transplantation (LT) provides the best chance of cure for patients with HCC and liver cirrhosis. With the implementation of the MELD exception system for patients with HCC waitlisted for LT, the number of recipients of LT is increasing, so is the number of patients who have recurrence of HCC after LT. Treatments for intrahepatic recurrence after transplantation and after other kinds of surgery are more or less the same, but long-term cure of posttransplant recurrence is rarely seen as it is a "systemic" disease. Nonetheless, surgical resection has been shown to be effective in prolonging patient survival despite the technical difficulty in resecting graft livers. Besides surgical resection, different kinds of treatment are also in use, including transarterial chemoembolization, radiofrequency ablation, high-intensity focused ultrasound ablation, and stereotactic body radiation therapy. Targeted therapy and modulation of immunosuppressants are also adopted to treat the deadly disease.-
dc.languageeng-
dc.relation.ispartofWorld Journal of Hepatology-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectTransarterial radioembolization-
dc.subjectHepatocellular carcinoma-
dc.subjectImmunosuppression-
dc.subjectLiver transplantation-
dc.subjectRadiofrequency ablation-
dc.subjectRecurrence-
dc.subjectResection-
dc.subjectStereotactic body radiation therapy-
dc.subjectTargeted therapy-
dc.subjectTransarterial chemoembolization-
dc.titleManagement of recurrent hepatocellular carcinoma after liver transplant-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.4254/wjh.v7.i8.1142-
dc.identifier.pmid26052403-
dc.identifier.pmcidPMC4450191-
dc.identifier.scopuseid_2-s2.0-84929761479-
dc.identifier.hkuros250848-
dc.identifier.volume7-
dc.identifier.issue8-
dc.identifier.spage1142-
dc.identifier.epage1148-
dc.identifier.eissn1948-5182-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats